Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
We examined the effects that ovariectomy had on sclerostin mRNA and protein levels in the bones of 8-week-old mice that were either sham-operated (SHAM) or ovariectomized (OVX) and then euthanized 3 or 6 weeks later. In this model, bone loss occurred between 3 and 5 weeks postsurgery. In calvaria, ovariectomy significantly decreased sclerostin mRNA levels at 6 weeks postsurgery (by 52%) but had no significant effect at 3 weeks. In contrast, sclerostin mRNA levels were significantly lower in OVX femurs at 3 weeks postsurgery (by 53%) but equal to that of SHAM at 6 weeks. The effects of ovariectomy on sclerostin were not a global response of osteocytes because they were not mimicked by changes in the mRNA levels for two other relatively osteocyte-specific genes: DMP-1 and FGF-23. Sclerostin protein decreased by 83% and 60%, at 3 and 6 weeks postsurgery in calvaria, respectively, and by 38% in lumbar vertebrae at 6 weeks. We also detected decreases in sclerostin by immunohistochemistry in cortical osteocytes of the humerus at 3 weeks postsurgery. However, there were no significant effects of ovariectomy on sclerostin protein in femurs or on serum sclerostin at 3 and 6 weeks postsurgery. These results demonstrate that ovariectomy has variable effects on sclerostin mRNA and protein in mice, which are dependent on the bones examined and the time after surgery. Given the discrepancy between the effects of ovariectomy on serum sclerostin levels and sclerostin mRNA and protein levels in various bones, these results argue that, at least in mice, serum sclerostin levels may not accurately reflect changes in the local production of sclerostin in bones. Additional studies are needed to evaluate whether this is also the case in humans. © 2013 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696 · cited 1×
“Currently, there are clinical trials underway((40,41)) to determine if inhibiting the actions of sclerostin, using antibodies or other agents, is an effective and safe therapy for diseases like osteoporosis, which are caused by low bone mass.”
BackgroundBonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287 · cited 8×
“We found that, in general, mRNA levels of DMP-1 and FGF-23 in calvaria and femur did not vary between SHAM and OVX bones as much as sclerostin mRNA levels.”
BackgroundInfluentialHigh Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 3×
“It primarily mediates its effects on bone through its ability to inhibit canonical Wnt-b-catenin signaling pathways.((4,5)) Wnts are a large family of secreted proteins that act as paracrine factors, which mediate embryonic development as well as cell growth and differentiation.”
BackgroundLittle, R. D., Folz, C., Manning, S. P., Swain, P. M., Zhao, S.-C., Eustace, B., Lappe, M. M., Spitzer, L., Zweier, S., Braunschweiger, K., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338450 · Cited by 1,282
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 3×
“Similarly, other conditions associated with defective sclerostin production such as sclerosteosis and Van Buchem’s disease also present with high bone mass.((1,15)) Sclerosteosis is caused by at least five different inactivating mutations of the SOST gene.”
BackgroundBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011 · cited 2×
“Based on its known actions on bone,((18)) decreases in sclerostin production would be expected to increase bone formation rates because loss or inhibition of sclerostin is associated with increased bone mass in both animal models and in humans.((1,2,13,15)) Previous studies from our group((29)) and others((22,30,31,42…”
BackgroundSclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698 · cited 3×
“Similarly, other conditions associated with defective sclerostin production such as sclerosteosis and Van Buchem’s disease also present with high bone mass.((1,15)) Sclerosteosis is caused by at least five different inactivating mutations of the SOST gene.”
Background
Cited by
Sex Steroid Actions in Male Bone
Vanderschueren, D., Laurent, M. R., Claessens, F., Gielen, E., Lagerquist, M. K., Vandenput, L., Börjesson, A. E., & Ohlsson, C. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1024 · Cited by 327
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches
Canalis, E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.154 · Cited by 304
Hormonal and systemic regulation of sclerostin
Drake, M. T., & Khosla, S. (2017) · Bone · doi:10.1016/j.bone.2016.12.004 · Cited by 77
Zhu, S., He, H., Gao, C., Luo, G., Xie, Y., Wang, H., Tian, L., Chen, X., Yu, X., & He, C. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0218 · Cited by 44
Kurgan, N., Stoikos, J., Baranowski, B. J., Yumol, J., Dhaliwal, R., Sweezey-Munroe, J. B., Fajardo, V. A., Gittings, W., Macpherson, R. E. K., & Klentrou, P. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4768 · Cited by 12
Metadata
- Authors
- Jastrzebski, S., Kalinowski, J., Stolina, M., Mirza, F., Torreggiani, E., Kalajzic, I., Won, H. Y., Lee, S.-K., & Lorenzo, J.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-10-08
- Volume
- 28
- Issue
- 3
- Pages
- 618-626
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1987081070
- Cited by
- 51
- References
- 11
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. https://app.cochat.ai/papers/10.1002/jbmr.1773
- The paper
- Jastrzebski, S., Kalinowski, J., Stolina, M., Mirza, F., Torreggiani, E., Kalajzic, I., Won, H. Y., Lee, S.-K., & Lorenzo, J. (2013). Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.1773
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.